Join NexChange - the professional
network for the financial services
industry - and receive a free one-
year subscription to Forbes
BioXcel Pharmaceuticals CEO On Drug Pipeline, How AI Is Changing Sector
A biotech that’s using artificial intelligence to identify neuroscience and immuno-oncology medicines received FDA approval for an investigational new drug application this week, and Benzinga connected with its CEO for more insight on the company’s innovation efforts.
New Haven, Connecticut-based BioXcel Pharmaceuticals announced Monday that its IND was accepted by the FDA to initiate a clinical trial for the triple immuno-oncology combination of BXCL701, bempegaldesleukin and avelumab for the treatment of pancreatic cancer as a second-line therapy.
Read more at Benzinga.
Photo: Public Domain